As a member of the Cancer Biology Program at the OSUCCC – James, Dr. Li focuses his research on two cancer-related areas. First, he uses electronic medical record data sources and medical informatics approaches to investigate risk factors (e.g., genomics and drug interactions) that predict either drug efficacy or adverse drug events. Dr. Li also uses public domain cancer genomics and transcriptomics data, as well as system biology and system pharmacology approaches, to investigate cancer drug resistance and cancer metastasis mechanisms. In particular, his lab focuses on target identification and drug response prediction. Although Dr. Li's informatics methodology research is not necessarily cancer specific, his current research investigates cancers of the breast, colon, liver and lung. He has authored or co-authored several publications in peer-reviewed journals, including BMC Medical Genomics, Clinical Pharmacology & Therapeutics, and International Journal of Molecular Sciences.